Leidos Biomedical Research, Inc. (LBRI), a wholly owned subsidiary of Leidos, operates the Frederick National Laboratory for Cancer Research (FNLCR). FNLCR is a Federally Funded Research and Development Center (FFRDC) sponsored by the National Cancer Institute (NCI). It is the only FFRDC dedicated to biomedical research. Through its status as an FFRDC, FNLCR provides NCI and others with a unique national resource to accelerate the development and delivery of effective preventive, diagnostic, and therapeutic products for cancer and AIDS.
The breadth of FNLCR’s activities spans the research and development spectrum, including investigator-initiated, hypothesis-driven research into cancer and AIDS; advanced technology programs focused on genetics and genomics, proteins and proteomics, imaging, nanotechnology, bioinformatics, and laboratory animal sciences; clinical operations in support of NCI and National Institute of Allergy and Infectious Diseases (NIAID)-sponsored clinical trials, as well as NCI drug discovery and development efforts; and management and operations of biopharmaceutical development and manufacturing programs under current Good Manufacturing Practice conditions for NCI and NIAID. Administrative, procurement, financial, safety, and facilities support is provided to these R&D activities through state-of-the-art business processes. LBRI has approximately 1,900 employees and manages an annual operating budget of approximately $450M.
For more information about Leidos Biomedical Research Inc., please visit our webpage at https://www.leidos.com/about/companies/leidos-biomedical-research.
The Cancer Genomics Research Laboratory (CGR) investigates the contribution of germline and somatic genetic variation to cancer susceptibility and outcomes in support of the NCI's Division of Cancer Epidemiology and Genetics (DCEG). Working in concert with epidemiologists, biostatisticians and basic research scientists in DCEG’s intramural research program, CGR provides the capacity to conduct genome-wide discovery studies and targeted regional approaches to identify the heritable determinants of various forms of cancer.
The Cancer Genomics Research (CGR) laboratory in Gaithersburg, MD, is a fast-paced, high-throughput organization dedicated to the support of molecular, genetic and epidemiologic studies for investigators at the National Cancer Institute's Division of Cancer Epidemiology & Genetics (DCEG). The Division includes over 70 principal investigators in epidemiology, genetics, and biostatistics who conduct multidisciplinary family- and population-based research to discover the genetic and environmental determinants of cancer, and new approaches to cancer prevention. This includes the design and analysis of high throughput studies using various types of “–omics” technologies such as array- and sequence-based genome-wide association studies, studies of tumor characteristics using integrated genomic data analysis and molecular epidemiologic studies based on novel metabolomic and microbiomic assays. We are seeking a highly motivated scientist to join the bioinformatics team at the CGR and provide analytical support to DCEG. Working with DCEG investigators, external collaborators, CGR management and staff, the Bioinformatics Scientist I will provide leadership and support to the extensive DCEG GWAS analytical efforts.
Duties include: 1) accessing, extracting and preparing data for analysis, including combining data run on multiple platforms as well as externally generated data in support of meta-analyses, 2) harmonizing and maintaining diverse data with associated metadata, 3) routine GWAS analytical tasks including data QC, imputation, population structure analysis, association analyses, 4) organizing results into clear presentations (including QQ-plots, Manhattan plots) and concise summaries of work, in formats useful for scientific interpretation, 5) development and execution of advanced analyses including multiplicative interaction analyses, pathway based analyses, integrative analyses and, 6) working closely with DCEG PIs in support of scientific manuscript development, submission, revision activities with significant coauthorship and potentially lead authorship opportunities
• Possession of a Doctoral degree from an accredited college/university according to the Council for Higher Education Accreditation (CHEA) in bioinformatics, statistics, genetics, computational biology or related field
• Foreign degrees must be evaluated for U.S. equivalency
• A minimum of two (2) years of progressively
responsible scientific and/or complex system management/bioinformatics experience.
• Strong knowledge required of genome-wide association analysis and interpretation, and applied computational research on large multivariate datasets.
• Expertise in algorithmic implementation, statistical programming and data manipulation, using e.g. R/Bioconductor, Matlab, Python, and a wide range of contemporary, open-source bioinformatics tools and database structures (e.g. PLINK, SNPTEST, GLU, IMPUTE2, BEAGLE, UCSC Genome Browser, etc.)
• Programming experience with Shell, Perl, Python, C/C++, and/or JAVA
• Team oriented with excellent written and verbal communication skills, with demonstrated ability to self-educate in current bioinformatics techniques and resources
• Familiarity with publically available data sources (such as dbGaP, TCGA, ENCODE, 1000 Genomes, TARGET, GTEX) and diverse genomic annotations
• Experience managing large datasets and computational tasks, experience working in a Linux environment (especially a compute cluster environment)
• Experience in the field of molecular and population genetics with a strong publication record
Leidos is a global science and technology solutions leader working to solve the world’s toughest challenges in the defense, intelligence, homeland security, civil, and health markets. The company’s 33,000 employees support vital missions for government and commercial customers. Headquartered in Reston, Virginia, Leidos reported pro forma annual revenues of approximately $10 billion for the fiscal year ended January 1, 2016 after giving effect to the recently completed combination of Leidos with Lockheed Martin's Information Systems & Global Solutions business (IS&GS). For more information, visit www.Leidos.com. The company’s diverse employees support vital missions for government and commercial customers. Qualified women, minorities, individuals with disabilities and protected veterans are encouraged to apply. Leidos is an Equal Opportunity Employer.